CA3218345A1 - Agonistes macrocycliques du recepteur du peptide 1 de type glucagon - Google Patents

Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Download PDF

Info

Publication number
CA3218345A1
CA3218345A1 CA3218345A CA3218345A CA3218345A1 CA 3218345 A1 CA3218345 A1 CA 3218345A1 CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A1 CA3218345 A1 CA 3218345A1
Authority
CA
Canada
Prior art keywords
preparation
mmol
methyl
title compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218345A
Other languages
English (en)
Inventor
Francisco Javier Agejas Chicharro
Renato Alejandro BAUER
Michael Gregory Bell
Qi Chen
Graham Robert Cumming
Todd Fields
Douglas Linn Gernert
Joseph Daniel HO
Talbi Abelkader KAOUDI
Thierry Jean MASQUELIN
Jose Miguel Minguez Ortega
Julian PRIEGO SOLER
Antonio Rodriguez Hergueta
Eric Michael Woerly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3218345A1 publication Critical patent/CA3218345A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule : ou un sel pharmaceutiquement acceptable de celui-ci, et des méthodes d'utilisation de ce composé pour le traitement du diabète sucré de type II.
CA3218345A 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Pending CA3218345A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191034P 2021-05-20 2021-05-20
US63/191,034 2021-05-20
US202163254564P 2021-10-12 2021-10-12
US63/254,564 2021-10-12
EP21383172.0 2021-12-21
EP21383172 2021-12-21
PCT/US2022/029958 WO2022246019A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du récepteur du peptide 1 de type glucagon

Publications (1)

Publication Number Publication Date
CA3218345A1 true CA3218345A1 (fr) 2022-11-24

Family

ID=82016585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218345A Pending CA3218345A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon

Country Status (8)

Country Link
EP (1) EP4341255A1 (fr)
JP (1) JP2024521073A (fr)
KR (1) KR20230173166A (fr)
AU (1) AU2022275931A1 (fr)
BR (1) BR112023022851A2 (fr)
CA (1) CA3218345A1 (fr)
IL (1) IL308397A (fr)
WO (1) WO2022246019A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102625A1 (fr) * 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060533T2 (hu) 2016-12-16 2023-03-28 Pfizer GLP-1 receptor agonisták és alkalmazásuk
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
PT3806855T (pt) 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CU20210083A7 (es) 2019-04-12 2022-05-11 Qilu Regor Therapeutics Inc Agonistas de glp-1r
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (fr) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
JP2022552735A (ja) 2019-10-25 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ｇｌｐ－１ｒ調節化合物
WO2021096284A1 (fr) 2019-11-15 2021-05-20 일동제약(주) Agoniste du récepteur glp-1 et son utilisation
EP4069686A4 (fr) 2019-12-02 2022-11-09 Hyundai Pharm Co., Ltd. Agoniste du récepteur glp-1
CN115335374A (zh) 2020-01-29 2022-11-11 吉利德科学公司 Glp-1r调节化合物
JP2023515404A (ja) 2020-02-13 2023-04-13 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
AU2021237185B2 (en) 2020-03-18 2023-11-30 Lg Chem, Ltd. GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4143183A4 (fr) 2020-04-29 2024-05-15 Gasherbrum Bio, Inc. Agonistes hétérocycliques du glp -1
EP4155313A4 (fr) 2020-06-04 2023-09-13 Hangzhou Sciwind Biosciences Co., Ltd. Composé imidazole hétéroaromatique à cinq chaînons et son utilisation
CN115697338A (zh) 2020-06-10 2023-02-03 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115916772A (zh) 2020-06-19 2023-04-04 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2021259309A1 (fr) 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées
TW202214622A (zh) 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
PE20231206A1 (es) 2020-08-21 2023-08-17 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2022042691A1 (fr) 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
AU2021306414A1 (en) 2020-09-01 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
WO2022068772A1 (fr) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
CN116547278A (zh) 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022078407A1 (fr) 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
EP4341255A1 (fr) 2024-03-27
TW202310838A (zh) 2023-03-16
IL308397A (en) 2024-01-01
BR112023022851A2 (pt) 2024-01-23
WO2022246019A1 (fr) 2022-11-24
KR20230173166A (ko) 2023-12-26
AU2022275931A1 (en) 2023-11-02
JP2024521073A (ja) 2024-05-28

Similar Documents

Publication Publication Date Title
CA3144055C (fr) Agonistes du recepteur du peptide de type glucagon 1
EP2038272B1 (fr) Inhibiteurs de pyridinonyle pdk1
TWI490202B (zh) 昇糖素受體調節劑
WO2011075560A1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
EA024059B1 (ru) Гетероциклические производные и их применение в лечении неврологических расстройств
TW200914449A (en) Organic compounds
US10017502B2 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
JP2017001991A (ja) 新規ベンズオキサゾロン化合物
JP2015527399A (ja) 置換−１，４−ジヒドロピラゾロ［４，３−ｂ］インドール
CA2828518C (fr) Derives de pyridynyl- et pyrasinyl-methyloxy-aryl utiles comme inhibiteurs de tyrosine kinase spleniqueyk)
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
EP3807273B1 (fr) Dérivés d'azaindole comme inhibiteurs de la kinase rho
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
WO2013051672A1 (fr) Agent médicinal comprenant un dérivé de thiazolidine ou sel de celui-ci comme ingrédient actif
JP6739516B2 (ja) 呼吸器合胞体ウイルス阻害剤
CA3218345A1 (fr) Agonistes macrocycliques du recepteur du peptide 1 de type glucagon
JP2016124810A (ja) 新規縮合ピラゾール誘導体およびその医薬用途
RU2662157C2 (ru) 2-пиридоновое соединение
WO2016098793A1 (fr) Dérivé thiazole ayant un groupe guanidyle cyclique
TWI843104B (zh) 類升糖素肽1受體促效劑
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
RU2813541C1 (ru) Спиросоединения в качестве антагонистов рецепторов меланокортина 4 и их применения
CN117355517A (zh) 大环胰高血糖素样肽1受体激动剂
WO2024102625A1 (fr) Agonistes de récepteur du peptide 1 de type glucagon

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231107

EEER Examination request

Effective date: 20231107

EEER Examination request

Effective date: 20231107